Mutations in the Aristaless-related homeobox (ARX) gene are one of the most frequent causes of X-linked intellectual disability (ID). Several missense mutations, clustered in the paired-type homeodomain of ARX, have been identified. These mutations lead to a range of phenotypes from X-linked lissencephaly with abnormal genitalia to seizure disorders without brain malformations including X-linked infantile spasms with ID (ISSX-ID) and X-linked myoclonic epilepsy with spasticity and ID (XMESID). The effect of these mutations on the DNA-binding and transcriptional activity has been evaluated. Luciferase reporter assays showed altered repression activity of ARX by all mutations, causing brain malformations and ISSX-ID phenotypes, but not by the P353L mutation implicated in a milder phenotype of XMESID. Similarly, transient overexpression of wild-type ARX repressed endogenous expression of known ARX targets, LMO1 and SHOX2, when measured by real-time quantitative polymerase chain reaction. Overall, the molecular consequence of missense mutations correlated well with the severity of the clinical phenotype. In all mutations tested, except P353L, the DNA binding was abolished. Electrophoretic mobility shift assay results were validated using chromatin immunoprecipitation following overexpression of normal and selected missense mutations. Unlike wild-type ARX and clinically less severe mutations, the mutations leading to severe clinical phenotypes were not able to specifically bind to DNA upstream of known, endogenous ARX-regulated genes, LMO1 and SHOX2. In conclusion, the missense mutations in the ARX homeodomain represent loss-of-function mutations, which lead to a reduced or complete loss of DNA binding and as a consequence, a loss of transcriptional repression.
INTRODUCTION
Intellectual disability (ID) is a large group of highly variable disorders of the brain affecting approximately 1 in every 50 individuals across the world populations. Defects arising from genes on the X-chromosome lead to clinically complex and genetically heterogeneous X-linked ID (XLID), with more than 100 genes currently known (1) . One of the most frequently mutated XLID genes is the Aristaless-related homeobox (ARX) gene. In excess of 100 mutations have been identified in ARX, causing a range of phenotypes all with ID, often with additional features including epilepsy, infantile spasms, hand dystonia, lissencephaly, autism or dysarthria (2) . The overall burden of ARX mutations might still be underestimated. This is because of the difficulty of the sequence capture and massively parallel sequencing technologies to enrich and sequence high-GC-rich ARX sequence (J.G., unpublished data), broad clinical expressivity of ARX mutations as well as the fact that many mutations identified by various diagnostic services may go unreported.
ARX is a member of the paired-type homeobox transcription factors, which are involved in the control of development and differentiation, and all contain the conserved 60 amino acid DNA-binding motif, referred to as the homeodomain. Mutations (insertion, deletion, nonsense and splice) in the ARX homeodomain that lead to loss or truncation of the mature ARX protein cause severe brain malformation phenotypes (2) . Disease-causing single-nucleotide substitutions that lead to missense changes are also found clustered in the ARX homeodomain (3 -9) . Several of these missense mutations are predicted to cause a complete loss-of-function as they lead to severe phenotypes with brain malformations such as X-linked lissencephaly with abnormal genitalia (XLAG) (3, 6, 7, 10, 11) normally associated with protein truncation mutations. In contrast, the remaining missense mutations in this domain affect the same residues as mutated in patients with XLAG but cause clinical presentations with seizures but no gross malformation of the brain (9, (12) (13) (14) .
These missense mutations have each been reported in a single family, often with multiple affected individuals. The molecular mechanism(s) underlying disease in these cases are not known. Missense mutations in the ARX homeodomain occur in the residues predicted to be important for DNA binding and the specificity of DNA binding (15) or nuclear import (9, 16, 17) . The nuclear localization sequences (NLSs) that flank the homeodomain contain the residues required for nuclear import of this transcription factor through interaction with importin proteins, including Importin 13 (IPO13) (17) and Importin b1 (16) . In the N-terminal NLS (NLS2) of ARX, there are several point mutations that have been identified in individuals with neurological disease: p.R332P (6), p.R332H (3) p.R332C (5) and p.R332L (7), which cause XLAG, and a residue adjacent to this arginine, p.T333N (6) , which causes Proud syndrome (agenesis of the corpus callosum with ambiguous genitalia) (ACC/AG; MIM 30004). In the C-terminal NLS (NLS3), there are two naturally occurring missense mutations in the same residue, p.R379L (9) , which causes XLAG, and p.R379S (8, 9) , which causes infantile spasms and ID. Our recent study modeling the missense mutations in the NLS2 and NLS3 regions of ARX homeodomain has shown that the mutant ARX protein remains in complex with Importin 13 (IPO13) instead of uncoupling in the RanGTP-rich nuclear environment, leading to inadequate accumulation and distribution of the ARX transcription factor within the nucleus (9) .
The remaining missense mutations in the ARX homeodomain include p.L343Q (3) and p.P353R (6)-both lead to severe brain malformation phenotype of XLAG, whereas mutation in the same residue p.P353L causes X-linked myoclonic epilepsy with spasticity and ID (XMESID) (4). The two most recently reported mutations in p.R358S (13) and p.R358W (14) cause similar clinical outcomes. When p.R358 is mutated to a serine, the patient presented with ACC, ID, infantile spasms and intractable epilepsy and abnormal genitalia (13) , whereas substitution to tryptophan caused ACC, severe ID, infantile spasms and subsequent intractable epilepsy but also spastic/dyskinetic quadriparesis, severe limb contractures and scoliosis (14) . As these mutations do not occur in the NLS regions of the homeodomain, altered interaction with IPO13 is unlikely and alternate molecular mechanisms explaining their pathogenesis need to be considered.
Mutations in the homeodomain of ARX are likely to affect DNA binding and hence, transcriptional activity. Ablation of Arx expression in the subpallium and ganglionic eminences of the mouse brain have identified direct targets of ARX transcriptional repression (18, 19) . The genes repressed via Arx binding to a specific (TAATTA) transcription factor-binding site (TFBS) include Lmo1, Ebf3 and Shox2 (19) . Ectopic expression of Ebf3 in ventral telencephalon prevented tangential migration of neurons, and silencing of Ebf3 expression in Arx mutant mice partially restored this neuronal migration (18) . To investigate the mechanism(s) underlying the pathogenesis of ARX homeodomain mutations, we evaluated the effect of missense mutations on the DNA-binding capacity and transcriptional activity of ARX. Our findings demonstrate altered transcriptional repression due to a loss of DNA binding as the molecular mechanism of most but not all ARX mutations tested.
RESULTS
Missense mutations in the ARX homeodomain abolish the repression activity of ARX Our first aim was to measure the functional impact of singlenucleotide substitution mutations in the homeodomain of ARX on its transcriptional activity. We generated a luciferase reporter construct by cloning three copies of the orthologous region identified as an Arx-binding site in the enhancer region of Lmo1 (19) upstream of SV40-luciferase. Co-transfection of a renilla expression vector was used to normalize the expression of luciferase. Reporter constructs were transiently transfected into HEK293T cells along with a Myc-expression vector containing full-length ARX (Fig. 1A) or an empty expression (Myc-empty) vector. The ratio of luciferase to renilla expression for the empty Mycvector is set to 100%. Compared with this value, the ARX-Wt repressed the expression of luciferase by 41% (Fig. 1B) . This is in agreement with previous studies in which this Arx-binding site was identified in the mouse (19) . The repression activity of ARX in our assay indicates that ARX is able to bind and repress transcriptional activity in the orthologous sequence upstream of LMO1 in the human. When the ARX protein contains a mutation within the homeodomain, the repression activity on luciferase expression was abolished. Indeed, all mutations tested gave higher levels of luciferase expression than the Myc-empty control (Fig. 1B) . The only exception to this was the p.P353L mutation, which displayed similar (32%), if slightly less, repression activity than ARX-Wt.
Homeodomain mutations derepress LMO1 and SHOX2, known target genes of ARX To complement our luciferase reporter assay results, we measured the endogenous expression of LMO1 and SHOX2, known ARX targets, following transient overexpression of wild-type and mutant ARX. When compared with the endogenous expression in untransfected HEK293T cells, the levels of both genes were repressed following overexpression of ARX-Wt (Fig. 2) . In comparison, overexpression of ARX missense mutations generally resulted in higher levels of LMO1 and SHOX2 expression, with several displaying levels similar to those of untransfected cells (Fig. 2) . In agreement with the luciferase assay data, the LMO1 and SHOX2 gene expression mirrored the severity of the clinical phenotype caused by the mutations tested, with the p.P353L mutation still be able to repress both target genes to levels achieved with ARX-Wt.
Homeodomain mutations outside the NLS regions do not disrupt ARX nuclear localization
We wanted to assess whether the loss of repression activity of mutant ARX protein was due to aggregate formation or protein mislocalization. Previously, we have demonstrated that mutations within the NLS regions of the homeodomain (p.R332P, p.T333N, p.R379L and p.R379S) significantly disrupt normal protein localization (9) . To determine whether a similar disruption occurred for mutations in the homeodomain that lie outside either known NLS region (i.e. p.L343Q, p.P353L, p.P353R and p.R358S), full-length Myc-tagged ARX plasmids were transiently transfected into HEK293T cells, and subcellular localization of the mutant protein was assessed. In the majority of transfected cells, the mutant protein was detected in a non-homogenous pattern across the nucleus, with little or no expression detectable in the cytoplasm (Fig. 3 ). This pattern was the same as observed with the over-expression of the wild-type protein. Only 10% of all cells transiently over-expressing ARX-Wt displayed aberrant localization, usually as small aggregates within the nucleus. Similarly, the p.P353L mutant protein was mislocalized in only 9.5% of transfected cells. The three remaining mutations p.L343Q (22%), p.P353R (20%) and p.R358S (22%) displayed approximately double this rate of abnormal protein localization. This is in stark contrast to our results with the overexpression and subcellular localization of the ARX NLS mutants, which had 5-7-fold more abnormal cells (Fig. 3) , with large aggregates of mutant protein within the nucleus and the cytoplasm (9).
Homeodomain mutations abolish DNA binding
To determine whether the loss of repression of the mutant ARX protein was due to loss or compromised binding to specific DNA targets, we tested all missense homeodomain mutant ARX protein, using electrophoretic mobility shift assay (EMSA). (19) were incubated with protein lysates from cells transiently transfected with Myc-tagged wild-type or mutant ARX-HD. The Myc-tagged wild-type ARX-HD bound LMO1 oligonucleotide (Fig. 4A, lane 3) . The binding was attenuated by competition with an excess of unlabeled LMO1 oligonucleotide (Fig. 4A , lanes 4 and 5) and super-shifted by the addition of anti-Myc antibody (Fig. 4A, lane 6) . All but one, p.P353L, mutations tested abolished the binding of ARX-HD to LMO1 (Fig. 4B) . Interestingly, the pattern of binding of the wild-type ARX-HD protein appeared as a doublet, likely representing ARX-HD monomer and dimer binding to the LMO1 probe. The higher molecular weight band (dimer) was not observed with the p.P353L mutation, suggesting that the mutant protein is less likely to form homodimers when compared with the wild-type ARX-HD.
To further unravel the subtleties underlying the genotypephenotype relationships for some of these missense mutations, we utilized chromatin immunoprecipitation (ChIP)-quantitative polymerase chain reaction (qPCR) to measure the capacity of selected mutant ARX protein(s) binding to endogenous ARX targets. Transiently overexpressed ARX-Wt was able to bind and immunoprecipitate specific TFBSs located upstream of LMO1 (Fig. 5A) and SHOX2 (Fig. 5B) . There was no specific enrichment by ARX of HUWE1 exon 29, a region devoid of specific TFBS motif (data not shown). The specific enrichment of LMO1 TFBS was also detected for missense mutation p.P353L. As expected, the clinically more severe mutations did not yield enrichment of these TFBS sequences, including p.R332P and p.R379S.
DISCUSSION
To unravel the pathogenesis and to better understand the role of particular homeodomain residues in the function of ARX, we examined the molecular consequences of these mutations. The transcriptional repression activity of ARX has been successfully modeled in vitro using cell-based studies (20) and a series of loss-of-function and gain-of-function approaches in mice (21, 22) . The recent identification of the ARX DNAbinding motif (18, 19) provides the necessary tools required to begin dissecting the molecular mechanisms of ARX homeodomain mutations. Here, we established that the transcriptional repression activity normally attributable to the wild-type protein is lost when conserved residues of the homeodomain are mutated. This was achieved using in vitro luciferase reporter assays and by testing the effect of the mutants on the endogenous expression of known ARX targets, LMO1 and SHOX2. We showed that disruption of the repression activity of the ARX mutants was due to a loss or marked reduction in DNA binding. This outcome is identical to a complete loss-of-function of ARX transcriptional activity, with the data consistent for all missense mutations in the ARX homeodomain causing severe brain malformation and infantile spasm-related phenotypes. We contend that loss of DNA binding to specific transcriptional targets is the molecular mechanism underlying disease pathogenesis in these patients. This in turn is not surprising given the severe clinical phenotypes caused by these mutations which are very much the same as those mutations leading to loss or truncation of the ARX protein (2). Interestingly, there was one consistently different mutation. The p.P353L mutation, underlying the least severe clinical phenotype of all mutations tested in this study, was still able to repress expression of the ARX target genes, although to a lesser extent than the ARX-Wt protein. Furthermore, this particular mutation also retained its DNA binding. Hence, a partial loss-of-function opposed to a complete loss of the transcriptional repression activity may account for the milder disease presentation in affected individuals with this particular mutation (12) .
There is a wealth of knowledge regarding the homeodomain structure. The conserved helix -turn -helix structure of the homedomain is composed of three helices (23) (24) (25) required in the recognition of homologous sequences of DNA. Conserved residues in the N-terminus of the domain and the recognition helix (Helix III) contact both major and minor grooves of DNA, whereas the different ninth residue of the recognition helix assists with specificity. The frequency of naturally occurring disease-causing mutations in various homeodomain proteins has led to the identification of residues in two functional hotspots (26, 27) . The N-terminal arm contributes strongly to the optimal binding of the homeodomain to DNA. R5 is located in the middle of this arm and has a dual function of binding to DNA minor groove as well as serving as part of the NLS. Essentially, R5 forms a core element of the N-terminal arm in recognizing the minor groove, without imposing DNA specificity (27) . p.R332 of ARX is equivalent to the position R5 of the homeodomain. Consistent with a dual role for R5, mutation of this residue in ARX leads to the disruption of correct nuclear localization (2) and loss of transcriptional activity and DNA binding (this study). The second hotspot relates to both R52 and R53 of the homeodomain, with R52 equivalent to p.R379 in ARX. This residue tethers recognition helix (Helix III) for optimal DNA binding by formation of a salt bridge with Glu17 and Glu56. Hence, p.R379 plays an important role in both conformational stability of the recognition helix as well as the stability of the entire homeodomain for optimal DNA binding. In the case of ARX, we see discordant clinical outcomes depending on the residue substituted in this position. However, our results show that both mutations in this residue abolish DNA binding and transcriptional repression activity of the respective mutant proteins. Similar to the R5 residue, we have shown that R52 in ARX is an important residue in a bi-partite NLS required for correct localization of the protein to the nucleus (9). A likely explanation for the discordant phenotypes arising from the two mutations in p.R379 of ARX may relate to the scale of disruption to the function of the mutant protein. The remaining residues are more difficult to assign a specific molecular function. R31 at the beginning of the Helix II is important for structural and functional role as part of the homeodomain -DNA backbone interaction. In ARX, this residue is equivalent to p.R358, in which mutations leading to two different residues essentially result in a similar phenotype.
The results from our study highlight the often complex genotype -phenotype relationship that exists for ARX disease-causing mutations. In the case of missense mutations within the ARX homedomain, there are several residues that are mutated to more than one alternate residue, including p.P353. Mutations leading to substitution of this residue result in drastically different clinical presentations. Changing the non-polar, neutral proline at p.P353 to a polar, positively charged arginine results in the severe brain malformation XLAG phenotype (6) , whereas substitution to a leucine with similar non-polar, neutral group leads to the milder phenotype of XMESID, with no gross malformation of the brain or genitalia (12, 28) . The relationship between the p.P353 mutations and their respective disease phenotypes has been modeled by generating knock-in mouse models (29) . Male mice with the equivalent p.P353R mutation died soon after birth and had significantly different Arx transcript levels and protein amounts, reduced GABAergic and cholinergic neuronal development with disturbed brain morphology. The features of the mutant mice were similar to mice deficient in Arx and recapitulated many of the clinical findings in the human situation of XLAG. On the other hand, the male mice with the p.P353L mutation lived for .6 months and exhibited only mild seizures and slight impairment to their learning capacity. In these mice, the GABAergic progenitor cells began migrating at the normal time of E12.5, with levels reaching the cortical plate at P0, similar (97%) to the wild-type mice, but did show impairments in tangential migration of interneurons into the striatum (29) . These data in conjunction with the findings of our study highlight that substitution of critical residues of the homeodomain can drastically alter the functional capacity of the resulting mutant protein, underscoring the need to elucidate the molecular mechanisms involved.
MATERIALS AND METHODS

Cloning of mutant full-length ARX constructs
The cloning of the full-length human ARX cDNA construct in pCMV-Myc vectors (ARX-Wt; 1 -562 amino acids) and the V5-IPO13 (217 -963 amino acids; minus the RanGTPasebinding site) have been described previously (17) . Singlenucleotide substitutions via site-directed mutagenesis to produce mutations c.995G.C leading to p.R332P (R332P) in the NLS2 region, c.998C.A leading to p.T333N (T333N) adjacent to NLS2, c.1136G.T leading to p.R379L (R379L) and c.1135C.A leading to p.R379S (R379S) in the NLS3 region and a c.1058C.T change leading to p.P353L (P353L) have been reported (9) . To engineer mutations c.1028T.A leading to p.L343Q, c.1058C.G leading to p.P353R and c.1074G.T leading to p.R358S using site-directed mutagenesis (Stratagene) was used to introduce these single-nucleotide substitutions into the pCMVMyc-ARX-Wt full-length constructs. For EMSA studies, partial human ARX cDNA containing the homeodomain and flanking sequence (wild-type and the eight single-nucleotide substitutions listed above) were engineered in pCMV-Myc vector (ARX-HD; 303 -431 amino acids). All clones were verified by sequencing the entire coding region.
Cell culture and transient transfection
HEK293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) FCS. All cells were cultured in the presence of 100 U/ml sodium penicillin and 100 mg/ml streptomycin sulfate in 5% CO 2 at 37 8 C. Cells were plated at 8 × 10 5 per well in a six-well plate the day before transfection in media lacking antibiotics. Routinely, cells were transfected with a total of 0.5-1 mg of plasmid DNA, using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. Fig. 1 ). The ARX-HD Wt migrates as a doublet, with the higher band predicted to be a homo-dimer of this protein domain binding to itself. Interestingly, the only mutant protein that displays affinity for the LMO1 TFBS probe does not form this homo-dimer, but migrates as the lower, single band.
Luciferase reporter assays
We used the orthologous sequence upstream of human LMO1 gene to generate luciferase reporter constructs containing specific TFBSs for ARX. An oligo containing three TFBS sequences in tandem 5 ′ -(gaattgattTAATTAacaggggaa) ×3-3 ′ and BamH1 and BglII sites flanking the end of the oligo was directionally cloned upstream of the SV40 promoter driving the luciferase reporter gene (luc2) in the pGL4.13[luc2/ SV40] vector (Promega). HEK293T cells (4 × 10 5 per well) were plated into 12-well plates and 24 h later were transfected with 500 ng of luciferase reporter plasmid DNA, 10 ng of pGL4.74[hRluc/TK] plasmid DNA (Promega) and 500 ng of Myc-expression plasmid DNA containing full-length ARX-Wt or homeodomain mutation sequence using Lipofectamine 2000 (Invitrogen). Cells were lysed 24 h post-transfection and the measurement of both Firefly and renilla luciferase was achieved using Dual-Glo Luciferase Assay System (Promega) on a Veritus Microplate Luminometer (Turner BioSystems, Sunnyvale, CA, USA). In four independent transfections, each sample was carried out in replicate, with triplicates of each replicate measured in the reporter assay. The Firefly luciferase activity was normalized according to the corresponding renilla luciferase activity, and the ratio of luciferase activity was reported relative to pCMV-Myc empty vector for each transfection.
Quantitative real-time polymerase chain reaction HEK293T cells (8 × 10 5 per well) were plated into six-well plates and 24 h later were transfected with 500 ng of Myc-expression plasmid DNA containing full-length ARX-Wt or homeodomain mutation sequence using Lipofectamine 2000 (Invitrogen). Total RNA was extracted from HEK293T cells harvested 24 h post-transfection using Trizol (Invitrogen) and RNeasy Mini Kit (Qiagen) and treated with DNase I (Qiagen) according to the manufacturer's instruction. We primed 2 mg of RNA with random hexanucleotides and subjected it to reverse transcription with SuperScript III reverse transcriptase (Invitrogen). The efficiency of the reaction was tested by PCR, using primers specific to the ubiquitously expressed EsteraseD. cDNAs were amplified by TaqMan Gene Expression Assays (Invitrogen). Assay IDs are available upon request. Target gene expression was detected using Fam-labeled probes, with HPRT detected in the same samples using a Vic label probe. Each sample was run in triplicate, and the entire experiment was repeated twice. Assays were analyzed on an Applied Biosystems RT-PCR machine, following the manufacturer's recommended protocol. Target gene expression was normalized to the corresponding percentage of cells transfected for each mutation (determined by counting between 500 and 600 cells per construct, per experiment), and the expression was reported relative to levels in non-transfected HEK293T cells.
Electrophoretic mobility shift assays
Oligonucleotides of the ARX TFBS upstream of LMO1 were 5 ′ -ataatgaattgattTAATTAacaggggaatctga-3 ′ and 5 ′ -ctcagatt cccctgtTAATTAaatcaattcatta-3
′ . These single-stranded oligonucleotides (5 pmol) were labeled with T4 polynucleotide kinase (Invitrogen) in the presence of 40 pmol [g-32 P]ATP (6000 Ci/mmol; Perkin Elmer). The un-incorporated [g-32 P]ATP was removed by column filtration, using MicroSpin G-25 columns (GE Healthcare). The purified complementary labeled oligonucleotides were annealed in Buffer H (Roche) by heating to 958C and then cooling to room temperature.
To produce protein suitable for the mobility shift assays, transient overexpression of pCMV-Myc plasmid DNA containing the ARX homeodomain and flanking sequence (ARX-HD; 303-431 amino acids) into HEK293T cells was carried out as described above. Crude protein from cells transfected with ARX-HD Wt and mutation plasmid DNA was produced by lysing cells in radioimmunoprecipitation assay buffer [65.3 mM Tris (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 1 mM NaVO 3 , 1 mM NaF and 1× protease inhibitor cocktail; Sigma]. Insoluble material was removed by centrifugation at 11 000g for 15 min. To determine the equivalent amounts of protein expression for wild-type and mutant ARX-HD, cleared lysates were separated on a 4-12% BisTris gel (Invitrogen) and transferred onto BioTrace NT nitrocellulose membranes (Pall Life Sciences). Membranes were blocked with 5% skim milk, incubated with mouse monoclonal IgG anti-cMyc antibody (200 ng/ml) and subsequently with goat anti-mouse IgG HRP-conjugated antibody. Signal was detected by chemiluminescence.
The binding assay utilized between 20 and 60 mg of crude protein lysate, adjusted to give comparable amounts of ARX-HD protein (wild-type or mutant protein) in each sample. The protein was incubated with 125 fmol labeled probe in total 22 ml of binding buffer (20 mM HEPES, pH 7.4, 50 mM KCl, 1 mM MgCl 2+ , 1 mM DTT, 5% glycerol,) and 5 mg of poly dI/dC on ice for 30 min. In competition assays, 8× and 40× of un-labeled probe was added. In supershift assay, 500 ng of anti-c-Myc antibody (Santa Cruz) was added. The whole reaction was loaded onto a 5% nondenaturing polyacrylamide gel and electrophoresed at 200 V for 1 h in 1× TBE. Gels were taken up on Whatmann paper, exposed to autoradiographic film at 280 8 C, with bands visualized by autoradiography.
Quantitative ChIP assays
ChIP assay was performed based on the protocol described by Kumar et al. (30) , with the following modifications. HEK293T cells were transfected with Myc-expression plasmid DNA containing full-length ARX-Wt or homeodomain mutation sequence, using Lipofectamine 2000 (Invitrogen) as described above. After 24 h, 1 × 10 7 transfected cells per construct were dissociated and fixed in 1% formaldehyde at room temperature for 10 min. Cells were lysed in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) and sonicated to fragment the DNA (input DNA). Immunoprecipitation of chromatin was carried out at 4 8 C overnight, using 25 ml of anti-c-Myc-conjugated agarose (Sigma) blocked with BSA and salmon sperm DNA before sequential washing with low-salt wash buffer (20 mM Tris -HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), high-salt wash buffer (20 mM Tris -HCl, pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), LiCl immune complex wash buffer (10 mM Tris -HCl, pH 8.0, 1 mM EDTA, 0.25 M LiCl, 1% NP40, 1% deoxycholate) and finally TE buffer (10 mM Tris -HCl, pH 8.0, 1 mM EDTA). Complexes were eluted in 1% SDS/100 mM NaHCO 3 , and crosslinks were reversed by adding NaCl to a final concentration of 200 mM and heating to 65 8 C for 4 h. DNA was extracted and subjected to qPCR, using oligonucleotides flanking the orthologous binding sites reported for Arx (19) . Amplicons were measured by SYBR Green fluorescence in 25 ml reaction volumes. Reactions were performed in triplicate. The amount of product was determined relative to a standard curve of input chromatin, and the expression in the enriched ChIP sample was reported relative to the DNA input control for each sample. The oligonucleotides used were as follows: SHOX2-F: 5
′ -CCC GGCCGCTCAGGTTTTCA-3 ′ and SHOX2-R: 5 ′ -GCTGCG CACTTGTCAGTTTC-3 ′ ; LMO1-F: 5 ′ -TTCCCGTGCCCTG CGGGTAAT-3 ′ and LMO1-R: 5 ′ -GGCCGTACTCGCCTC AGCAG-3 ′ ; HPRT-F: 5 ′ -AACTTTCCCCAGTTCAGTGC-3 ′ and HPRT-R: 5 ′ -TGGGAACGACTTAGCATGAG-3 ′ .
Antibodies
The following antibodies were used for immunofluorescence and immunoblot analysis: mouse anti-ARX antibody 
Statistical analysis
All data are reported as mean + standard error of the mean, determined from a minimum of three separate transfection reactions. The number of cells counted for sub-cellular localization studies is indicated in each figure legend. In the case of reporter assays, the luciferase expression were normalized to renilla expression. Differences in the percentage of transfected cells with abnormal subcellular localization and differences in the percentage relative to empty Myc-vector-transfected cells were analyzed with a Kruskal -Wallis test. When significance was reached, one-tailed pair-wise comparison was achieved using a Wilcoxon test to obtain tests of difference between ARX-Wt and other treatments in the first instance, and then among all others.
